News of the WeekDRUG SAFETY

Conflict-of-Interest Allegations Derail Inquiry Into Antidepressant's 'Dark Side'

See allHide authors and affiliations

Science  04 Apr 2003:
Vol. 300, Issue 5616, pp. 33
DOI: 10.1126/science.300.5616.33a

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

A controversial government review of the safety of antidepressant drugs is in disarray following revelations that some experts involved in the inquiry are shareholders in a company that makes one of the drugs. Last week, the U.K.'s Medicines Control Agency disbanded a panel that had been scrutinizing the track record of selective serotonin reuptake inhibitors, a widely prescribed group of drugs that includes the brands Prozac and Seroxat.